Directly arising from this work, we now identify SAR441566 as a small molecule TNF inhibitor that has the preclinical attributes to become a first in class oral drug with the potential to transform the lives of patients living with multiple TNF driven immune diseases. The gene discussed is TNF; the disease is immune system disorder.